Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV.

ABSTRACT:

Introduction

Randomized controlled trial evidence suggests that long-acting injectable (LA-I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy. The optimal regimen is uncertain.

Methods

We synthesized evidence from PubMed, EMBASE, Cochrane and conference abstract databases through 18 November 2024, to identify observational cohort studies (OCS) that reported on VF events in virally suppressed individuals who switched to LA-I CAB+RPV. We extracted data on VF, resistance-associated mutations (RAMs) at VF, post-VF regimen choice and re-suppression. We assessed the risk of bias using a modified Downs and Black tool.

R

SUBMITTER: Ring K 

PROVIDER: S-EPMC12315068 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature